MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

BACKGROUND: Treatment with MD1003 (high-dose biotin) showed promising results in progressive multiple sclerosis (MS) in a pilot open-label study. OBJECTIVE: To confirm the efficacy and safety of MD1003 in progressive MS in a double-blind, placebo-controlled study. METHODS: Patients (n = 154) with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tourbah, Ayman, Lebrun-Frenay, Christine, Edan, Gilles, Clanet, Michel, Papeix, Caroline, Vukusic, Sandra, De Sèze, Jerome, Debouverie, Marc, Gout, Olivier, Clavelou, Pierre, Defer, Gilles, Laplaud, David-Axel, Moreau, Thibault, Labauge, Pierre, Brochet, Bruno, Sedel, Frédéric, Pelletier, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098693/
https://www.ncbi.nlm.nih.gov/pubmed/27589059
http://dx.doi.org/10.1177/1352458516667568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098693/
https://www.ncbi.nlm.nih.gov/pubmed/27589059
http://dx.doi.org/10.1177/1352458516667568

Ejemplares similares